A week after disclosing layoffs, BridgeBio nets a $90M upfront cancer R&D pact with Bristol Myers

BridgeBio has located the bridge to greener pastures, specifically the lavish purple of Bristol Myers Squibb.

The two are collaborating in a deal giving the reorganized biotech an upfront payment of $90 million, a capital infusion that comes a week after the Palo Alto, CA biotech disclosed $23 to $25...

Click to view original post